GSK presents positive data for AREXVY, its respiratory syncytial …
Oct 8, 2024 · AREXVY is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older including those who are at increased risk due to certain …
FDA adds warning label to RSV vaccines Abrysvo and Arexvy …
Jan 14, 2025 · Arexvy has been approved for the prevention of lower respiratory tract disease caused by RSV in all individuals 60 years of age and older and for those aged 50 to 59 years …
Arexvy Looks Promising for RSV Protection in Younger At-Risk …
Nov 4, 2024 · Arexvy is currently approved for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 60 years of age and older, and …
New data for AREXVY, GSK’s respiratory syncytial virus vaccine, …
AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in: Individuals 50 through 59 years …
RSV Vaccines Will Carry Warning for Guillain-Barré Syndrome
4 days ago · The prescribing information for two respiratory syncytial virus (RSV) vaccines will now include a warning for the increased risk for Guillain-Barré Syndrome (GBS) within 42 days …
New data for Arexvy, GSK’s respiratory syncytial virus vaccine, …
Oct 24, 2024 · GSK plc (LSE/NYSE: GSK) today announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased …
GSK says RSV vaccine protects against disease over three seasons
Oct 8, 2024 · Vaccine maker GSK unveiled new data Tuesday showing its respiratory syncytial virus vaccine Arexvy protected older adults over three seasons against disease caused by …
GSK's Arexvy provides protection over three RSV seasons, trial …
Oct 8, 2024 · GSK has announced positive results from a phase III trial of its Arexvy RSV vaccine, showing that just one dose of the treatment could help protect older adults at risk of RSV …
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the...
About Arexvy (respiratory syncytial virus vaccine, adjuvanted) - GSK
Jun 21, 2023 · New results from the ongoing AReSVi-006 phase III trial show vaccine efficacy against RSV-lower respiratory tract disease and severe disease over two full RSV seasons, …